News

Spyryx Biosciences Raises $18 Million To Develop CF Therapy

Spyryx Biosciences, Inc. has successfully raised $18 million in Series A venture capital financing, which will be used to develop novel therapies to treat respiratory conditions such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The funding was secured through deals with Canaan Partners, Hatteras Venture Partners and…

Advanced Inhalation Therapies Granted European Orphan Drug Designation To Treat Cystic Fibrosis

Advanced Inhalation Therapies Ltd (AIT), an anti-microbial therapeutic company, recently announced that the European Commission, acting on recommendations from the Committee for Orphan Medicinal Products of the European Medicines Agency, has granted orphan medicinal product designation to the firm’s proprietary high dose formulation of nitric oxide (NO), AIT-CF, to address the treatment…

CFF Calls Attention to National Cystic Fibrosis Awareness Month

Last Friday marked the start of national Cystic Fibrosis Awareness Month, when thousands of volunteers across the country will fundraise and advocate for more research to fight the disease. The month-long initiative will be spearheaded by the Cystic Fibrosis Foundation (CFF), which will organize a series of events nationwide. The…